You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

SYMLIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Symlin patents expire, and what generic alternatives are available?

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. Additional details are available on the pramlintide acetate profile page.

Drug patent expirations by year for SYMLIN
Drug Prices for SYMLIN

See drug prices for SYMLIN

Recent Clinical Trials for SYMLIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boston UniversityEarly Phase 1
National Institute on Aging (NIA)Early Phase 1
H. Lee Moffitt Cancer Center and Research InstituteEarly Phase 1

See all SYMLIN clinical trials

US Patents and Regulatory Information for SYMLIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SYMLIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SYMLIN

See the table below for patents covering SYMLIN around the world.

Country Patent Number Title Estimated Expiration
Canada 2109794 ⤷  Try a Trial
South Africa 9406881 ⤷  Try a Trial
Japan 2828250 ⤷  Try a Trial
Canada 2171207 METHODES POUR LA REGULATION DE LA MOTILITE GASTRO-INTESTINALE (METHODS FOR REGULATING GASTROINTESTINAL MOTILITY) ⤷  Try a Trial
Australia 2011592 ⤷  Try a Trial
Russian Federation 2177331 METHODS OF REGULATION OF GASTROENTERIC TRACT MOTOR SYSTEM ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.